Composition for extending healthy lifespan

A combination of Bifidobacterium and Lacticaseibacillus bacteria with prebiotics enhances healthy lifespan by addressing frailty, offering a solution to the unknowns in probiotic functionality.

JP7591364B2Active Publication Date: 2024-11-28MORINAGA MILK IND CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020119977
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-07-13
Publication Date
2024-11-28
Estimated Expiration
2040-07-13

AI Technical Summary

Technical Problem

The functionality of probiotics when combined in multiple types is not well understood, necessitating research to discover new health benefits.

Method used

A composition containing a combination of Bifidobacterium and Lacticaseibacillus bacteria, preferably Bifidobacterium longum NITE BP-02621 and Lactobacillus paracasei NITE BP-01633, with optional prebiotics like lactulose, is developed to extend healthy lifespan by preventing or improving frailty.

Benefits of technology

The composition effectively extends healthy lifespan by preventing or improving frailty, contributing to maintaining mental and physical health in an aging society.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591364000001
    Figure 0007591364000001
  • Figure 0007591364000002
    Figure 0007591364000002
Patent Text Reader

Abstract

To provide a new health functionality of probiotics.SOLUTION: A composition for extending health life contains Bifidobacterium bacteria and Lacticaseibacillus bacteria. Preferably the composition can extend the health life by preventing and / or improving frailty.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for extending healthy lifespan. [Background technology]

[0002] In recent years, the relationship between intestinal bacteria and health has attracted attention, and research is being conducted around the world. "Probiotics," a term known for improving the intestinal environment, generally refers to live microorganisms that have a beneficial effect on humans by improving the balance of intestinal flora. Furthermore, there are also "prebiotics" that are assimilated by such probiotics, which generally refers to substances that are not broken down or absorbed in the upper digestive tract, but serve as a selective nutrient source for beneficial bacteria that live symbiotically in the large intestine, promoting their proliferation, improving and maintaining a healthy balance in the composition of intestinal flora in the large intestine, and helping to promote and maintain human health.

[0003] The main probiotics known are Bifidobacterium bacteria (also known as bifidobacteria) and lactic acid bacteria. Bifidobacterium bacteria have been reported to have various beneficial effects on hosts such as humans, such as prevention of diarrhea, reduction of harmful bacteria and toxic compounds, immunomodulation, and anticarcinogenic activity (Non-Patent Documents 1 to 3). It has been reported that some lactic acid bacteria exhibit preventive and defensive effects against various infectious diseases by activating the host's cellular immunity and enhancing the secretion of immune substances from the mucous membranes of the intestinal tract and respiratory tract (Non-Patent Documents 4 to 7). In addition, strains with excellent such effects have been found (Patent Documents 1 and 2). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2012 / 133827 [Patent Document 2] International Publication No. 2015 / 004949 [Non-patent literature]

[0005] [Non-Patent Document 1] S. Fukuda et al., Nature, 2011, 469, 543-547. [Non-Patent Document 2] S. Fanning et al., PNAS, 2012, 109 (6), 2108-2113. [Non-Patent Document 3] Sivan A. et al., Science. 2015, 350 (6264), 1084-1089. [Non-Patent Document 4] Delcenserie, V. et al., Curr. Issues Mol. Biol. (2008) 10: 37-54. [Non-Patent Document 5] Hori, T. et al., Clin. Diagn. Lab. Immunol. (2002) 9: 105-108. [Non-Patent Document 6] Takeda, K. et al., Clin. Exp. Immunol. (2006) 146: 109-115. [Non-Patent Document 7] Ogawa, T., Clin. Exp. Immunol. (2006) 143: 103-109. Summary of the Invention [Problem to be solved by the invention]

[0006] There are many unknowns regarding the functionality of probiotics, and research is still ongoing into the changes in functionality when multiple types of probiotics are combined. In this situation, an objective of the present invention is to discover and provide new health functionality of probiotics. [Means for solving the problem]

[0007] As a result of intensive research conducted by the present inventors to solve the above problems, Bifidobacterium The present inventors have found that a composition containing a combination of bacteria of the genus Lacticaceae and bacteria of the genus Lacticaceae has the effect of extending healthy lifespan, and have thus completed the present invention.

[0008] That is, the present invention relates to a Bifidobacterium bacterium and a lactobacillus subtilis. A composition for extending healthy lifespan containing bacteria of the genus Lacticaseibacillus. The Bifidobacterium bacterium of the present invention is preferably Bifidobacterium longum. Furthermore, the Bifidobacterium longum of the present invention is preferably Bifidobacterium longum NITE BP-026. The number is 21. The Lacticaseibacillus bacterium of the present invention is preferably Lacticaseibacillus paracasei. Furthermore, the Lacticaseibacillus paracasei of the present invention is Lacticaseibacillus paracasei NITE BP-01633. It is. The Bifidobacterium bacteria and / or Lacticaseibacillus bacteria in the present invention may be live bacteria and / or killed bacteria. Preferably, the composition of the present invention further contains a prebiotic. The prebiotic is preferably lactulose. In the present invention, the extension of healthy lifespan is preferably achieved by preventing and / or ameliorating frailty. The composition of the present invention is preferably a food or drink. Effect of the Invention

[0009] According to the present invention, it is possible to prevent or improve frailty, thereby achieving an effect of extending healthy lifespan, which can contribute to leading a social life while maintaining a healthy state of mind and body in an aging society. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The present invention will now be described in detail. However, the present invention is not limited to the following embodiments and can be freely modified within the scope of the present invention.

[0011] The composition of the present invention contains bacteria of the genus Bifidobacterium and bacteria of the genus Lacticaseibacillus. In the present invention, the composition may contain one or more types of bacteria of the genus Bifidobacterium and one or more types of bacteria of the genus Lacticaseibacillus, respectively.

[0012] Examples of the Bifidobacterium genus bacteria include, but are not limited to, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum subsp. infantis), Bifidobacterium bifidum, Bifidobacterium Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bifidobacterium spp. Bifidobacterium pseudocatenulatum, Bifidobacterium a Examples of Bifidobacterium species include Bifidobacterium animalis, Bifidobacterium lactis, and Bifidobacterium pseudolongum.

[0013] More specifically, Bifidobacterium longum BB536 is an example of Bifidobacterium longum. Bifidobacterium longum BB536 is an independent lineage. National Institute of Technology and Evaluation, Patent Microorganism Deposit Center (NPMD) (〒292-0818 The international deposit was made under the Budapest Treaty on January 26, 2018 at the National Institute of Informatics (Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture) under the accession number NITE BP-02621. The same bacterium, Bifidobacterium longum subsp. longum ATCC BAA-999 (number: ATCC BAA-999), is American Type Culture Collection (ATCC; United States, 2 10801 University Boulevard, Manassas, Virginia 0110 01 University Boulevard, Manassas, VA 2011 0, United States of America) from ATCC BAA-9 99 (see, for example, JP 2012-223134 A).

[0014] More specifically, Bifidobacterium breve M-16V can be mentioned. Bifidobacterium breve M-16V was registered with the NPMD on January 26, 2018 under the accession number NITE BP-02622 and the Budapest An international deposit has been made under the treaty. Commercially available products, such as "Bifidobacterium breve M-16V" manufactured by Morinaga Milk Industry Co., Ltd. may also be used. More specifically, Bifidobacterium breve MCC1274 can be mentioned as an example of Bifidobacterium breve. Bifidobacterium breve MCC1274 has been internationally deposited on August 25, 2009 at the National Institute of Advanced Industrial Science and Technology (currently the National Institute of Technology and Evaluation Patent Organism Depositary (IPOD) (Room 120, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818) under the accession number FERM BP-11175 based on the Budapest Treaty.

[0015] More specifically, Bifidobacterium infantis includes Bifidobacterium longum subsp. infantis M-63. Bacterium longum subsp. infantis M-63, 2018 On January 26, 2013, the NPMD was submitted to the National Institute of Standards and Technology (NITS) under the accession number NITE BP-02623 in accordance with the Budapest Convention. The term "Bifidobacterium infantis" is synonymous with Bifidobacterium infantis M-63, which has been deposited internationally under the terms of an international depository agreement.

[0016] Among these Bifidobacterium bacteria, Bifidobacterium longum is more preferable, and Bifidobacterium longum BB536 (Accession No.: NITE BP-02621) is particularly preferred.

[0017] Lacticaseibacillus bacteria were previously classified as part of the Lactobacillus genus, but in 2020 the International Committee on Prokaryotic Nomenclature (ICSP) This refers to bacteria that have been reclassified into the genus Lacticaceibacillus in the International Journal of Systematic and Evolutionary Microbiology (IJSEM) in accordance with the ICNP rules. The newly classified genus Lacticaseibacillus includes Lacticaseibacillus casei, Lacticaseibacillus paracasei, and Lacticaseibacillus rhamnosus.

[0018] Lacticaceae Bacillus casei, more specifically Lactobacillus casei YI T9029 (FERM BP-1366), Lactobacillus casei ATCC393, etc. Lactobacillus casei YIT9029 is classified as a Lactobacillus bacterium, which is an old classification. IPOD was submitted to the International Deposit Agency under the Budapest Treaty under the accession number FERM BP-01366. The entrustment has been made. Lactobacillus casei ATCC393 is a strain of the American Type Culture Collection. These antibodies can be obtained from the American College of Chemists (ATCC; 12301 Parklawn Drive, Rockville, Maryland 20852, United States of America).

[0019] More specifically, examples of Lactobacillus paracasei include Lactobacillus paracasei MCC1849, Lactobacillus paracasei MCC1375, Lactobacillus paracasei KW3110, and Lactobacillus paracasei WON0604. Lactobacillus paracasei MCC1849 is a member of the old Lactobacillus genus. The material was deposited in the NPMD on June 6, 2013 under the accession number NITE P-01633. The material was transferred to international deposit under the Budapest Treaty on January 31, 2014, and assigned the accession number NITE BP-01633. Lactobacillus paracasei MCC1375 is a member of the old Lactobacillus genus. The National Institute of Advanced Industrial Science and Technology (currently IPOD) received the international patent application pursuant to the Budapest Treaty on the accession number FERM BP-11313 on November 5, 2010. The deposit was made on the spot. Lactobacillus paracasei KW3110 has been deposited in the IPOD under the Budapest Treaty under the accession number FERM BP-08634, while L. casei L1 4 strain is also available from the Japan Dairy Technology Association. Lactobacillus paracasei WON0604 has been deposited under the Budapest Treaty at IPOD under the accession number FERM BP-11468.

[0020] More specifically, examples of Lacticaceibacillus rhamnosus include Lactobacillus rhamnosus LCS742, Lactobacillus rhamnosus ATCC53103, and the like. Lactobacillus rhamnosus LCS742 is a Lactobacillus strain from Morinaga Milk Industry Co., Ltd. rhamnosus LCS-742 (see, for example, JP-A-2009-522280). Lactobacillus rhamnosus ATCC53103 is an American type culture. Available from the Harper Collection. Among these Lactobacillus bacteria, Lactobacillus paracasei is more preferable, and among them, Lactobacillus paracasei MCC1849 (Accession No.: NIT E BP-01633) is particularly preferred.

[0021] The above-mentioned strains of the genus Bifidobacterium and Lacticaceabacillus are not limited to the strains deposited or registered under the name of the bacteria at a designated institution (hereinafter, for convenience of explanation, also referred to as "deposited strains"), but also include strains that are substantially equivalent thereto (also referred to as "derived strains" or "derived strains"). In other words, they are not limited to the strains deposited at the depository institution under the above accession numbers, but also include strains that are substantially equivalent thereto. Regarding bacteria, "strains substantially equivalent to the above-mentioned deposited strain" refers to bacteria that belong to the same species as the above-mentioned deposited strain, and further have a genome sequence similarity (average nucleotide identity value) of preferably 99.0% or more with the above-mentioned deposited strain, It more preferably has 99.5% or more identity, and even more preferably 100% identity, and preferably has the same bacteriological properties as the deposited strain. For bacteria, a strain substantially equivalent to the deposited strain may be, for example, a derived strain with the deposited strain as a parent strain. Derived strains include strains bred from the deposited strain and strains that have naturally arisen from the deposited strain. Breeding methods include modification by genetic engineering techniques and modification by mutation treatment. Mutation treatments include irradiation with X-rays, irradiation with ultraviolet rays, and N-methyl-N'-nitro-N-nitro- Examples of mutants include those that have been modified by treatment with mutagens such as rosoguanidine, ethyl methanesulfonate, and methyl methanesulfonate. Strains that have arisen naturally from the deposited strain include strains that have arisen naturally during use of the deposited strain. Such strains include mutants that have arisen naturally upon culturing (e.g., subculturing) the deposited strain. Derivative strains may be constructed by one type of modification, or by two or more types of modifications.

[0022] The Bifidobacterium genus bacteria and Lacticaseibacillus genus bacteria contained in the composition of the present invention may be commercially available products, or may be obtained by appropriate production, or may be obtained by culturing the above-mentioned bacteria. The culture method is not particularly limited as long as the bacteria of the genus Bifidobacterium or Lacticaseibacillus can grow. As the culture method, for example, a method usually used for culturing bacteria of the genus Bifidobacterium or Lacticaseibacillus can be used as is or with appropriate modification. The culture temperature may be, for example, 25 to 50°C, and preferably 35 to 42°C. The culture can be preferably performed under anaerobic conditions, for example, while aerating anaerobic gas such as carbon dioxide gas. The culture can also be performed under microaerobic conditions such as liquid stationary culture. The culture can be performed, for example, until the bacteria grow to a desired extent.

[0023] The medium used for the culture is not particularly limited as long as the Bifidobacterium bacteria or Lacticaceabacillus bacteria can grow. For example, the medium may be a medium that is generally used for the culture of the bacteria, either as is or after appropriate modification. That is, as the carbon source, sugars such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolysate, and blackstrap molasses can be used depending on the assimilation. As the nitrogen source, for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride, and ammonium nitrate, and nitrates can be used. In addition, as the inorganic salt, for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, and ferrous sulfate can be used. In addition, organic components such as peptone, soybean flour, defatted soybean meal, meat extract, and yeast extract may be used. In addition, specific examples of media commonly used for culturing the above bacteria include Reinforced Clostridial medium, de Man, Rogosa, and Sharpe medium (MRS medium), modified MRS medium (mMRS medium), TOS propionate medium (TOSP medium), TOS propionate mupirocin medium (TOSP Mup medium), and GAM (Gifu Anaerobic Examples of such medium include Yeast Extract-casein Hydrolysate Acid (YCFA) medium.

[0024] The form of the Bifidobacterium and Lacticaseibacillus bacteria contained in the composition of the present invention may be any of bacterial cells, a bacterial culture, and a treated bacterial product, each independently. The bacterial cells may be, for example, live bacterial cells, killed bacterial cells (including injured bacterial cells), or a mixture of live bacterial cells and killed bacterial cells. The Bifidobacterium bacteria and the Lacticaseibacillus bacteria may be independently selected from live bacterial cells, killed bacterial cells, and a mixture thereof. In a preferred embodiment, the Bifidobacterium bacteria are contained in the composition of the present invention as live bacterial cells, and the Lacticaseibacillus bacteria are contained in the composition of the present invention as killed bacterial cells. As the bacterial culture, for example, the culture obtained by culturing may be used as it is, the culture may be diluted or concentrated, or the bacterial cells recovered from the culture may be used. In addition, the culture may be a culture supernatant or a culture fraction. When using a culture supernatant, for example, the supernatant of the culture solution obtained by culturing in GAM medium at 37°C for 16 hours can be preferably used. The processed bacterial material may be a product obtained by subjecting bacterial cells or cultures to crushing, heating, freeze-drying, or spray-drying, as well as a diluted product, dried product, or fraction thereof.

[0025] The contents of the Bifidobacterium genus bacteria and the Lacticaceibacillus genus bacteria in the composition of the present invention are not particularly limited. For example, the amount of the bacteria is 1.0 × 10 per 1 g of the composition. 4 cfu or more, more preferably 1.0×10 7 It is acceptable to say that the number of cells is equal to or more than cfu. Note that cfu is defined as colony forming units (CFU). In the present specification, the term "cfu" refers to a unit of cell mass. For example, the term may refer to a value obtained when the bacteria is cultured at 38°C in a solid medium containing 10% by mass of reconstituted skim milk powder. When the bacteria is killed, the term "cfu" may be substituted with "cells." When a culture supernatant is used as the bacterial culture, the content is preferably 0.1 to 100% by mass, more preferably 1 to 90% by mass, and even more preferably 10 to 80% by mass of the entire composition. Furthermore, the content ratio of the Bifidobacterium genus bacteria and the Lacticaseibacillus genus bacteria in the composition of the present invention is not particularly limited, but is preferably 0.1:99.9 to 99.9:0.1, more preferably 1:99 to 99:1, even more preferably 10:90 to 90:10, and even more preferably 30:70 to 70:30, in terms of the bacterial cell mass expressed in cfu, for example. These contents may be within the range generally used when distributed as oral compositions.

[0026] The composition of the present invention preferably further contains a prebiotic. Prebiotics mainly refer to substances that have the effect of promoting the proliferation of probiotics in the intestine and inhibiting the decrease of probiotics. In the present invention, those that have the effect of promoting the proliferation and / or inhibiting the decrease of Bifidobacterium bacteria are particularly preferred. Preferred examples of prebiotics include oligosaccharides (lactulose, galactooligosaccharides, fructooligosaccharides, xylooligosaccharides, isomaltooligosaccharides, raffinose, lactosucrose, soybean oligosaccharides, coffee oligosaccharides, human milk oligosaccharides, etc.), monosaccharides (galactose, mannose, etc.), and dietary fibers (inulin, alginic acid, etc.). Of these, oligosaccharides are more preferred, and lactulose is even more preferred.

[0027] The content of prebiotics in the composition of the present invention is not particularly limited, but may be, for example, 0.1 to 90% by mass of the entire composition, or 1 to 900 mg per 1 g of the composition.

[0028] The composition of the present invention can extend healthy longevity. "Healthy longevity" is an index proposed by the World Health Organization (WHO) and is the number of years from average life expectancy to the time when one is bedridden or confined to a hospital. This refers to the period of time that is deducted from the period of time spent in a state of needing nursing care, such as dementia. Extending healthy life expectancy does not simply mean living longer, but rather extending the period of time spent in a state of mental and physical health. It can also be said to shorten the period of time spent in a state of needing nursing care, or to shorten the overall period by delaying the onset and progression of conditions such as becoming bedridden or having dementia.

[0029] The healthy life expectancy extension effect exerted by the composition of the present invention is preferably due to the prevention and / or amelioration of frailty. Here, the prevention of frailty includes prevention of frailty and delay of the onset of frailty, and the amelioration of frailty includes suppression of frailty and delay of the progression of frailty. "Frailty" refers to a state of frailty that occurs when physiological reserve capacity declines in old age, increasing vulnerability to stress and falling between a healthy state and a state of impaired daily function or a state requiring nursing care (see statement by the Japan Geriatrics Society https: / / jpn-geriat-soc.or.jp / info / topics / pdf / 20140513_01_01.pdf). This state of frailty is a concept that includes not only physical problems such as loss of agility in movements due to decreased muscle strength and increased susceptibility to falls, but also mental and psychological problems such as cognitive impairment and depression, and social problems such as living alone and economic hardship. In general, frailty is not considered irreversible, but rather reversible, and can be restored to a healthy state with appropriate intervention.

[0030] There are no unified criteria for diagnosing frailty, but the Cardiovascular Health Study criteria (CHS criteria) based on a phenotype model and the Frailty Index based on a deficit accumulation model are known as the main methods, and their scores have been improved. It is reasonable to judge that frailty has improved by improving the condition. The FRAIL scale and Edmonton Frail Scale ( Improvement in frailty may be assessed using the Extensor Frailty Index (EFS), Tilburg Frailty Indicator (TFI), Key Checklist (KCL), and Brief Frailty Index.

[0031] The Japanese version of the CHS criteria (J-CHS) uses five evaluation criteria: weight loss, muscle weakness, fatigue, decreased walking speed, and decreased physical activity. As shown in the examples below, the ingestion of the composition of the present invention has an appetite improving effect, and therefore an improvement in the evaluation of "weight loss" is expected. In addition, the ingestion of the composition of the present invention has a sleep improving effect and a fatigue recovery effect, and therefore an improvement in the evaluation of "fatigue". In addition, the ingestion of the composition of the present invention has a muscle mass increasing effect, and therefore an improvement in the evaluation of "muscular weakness", "decreased walking speed", or "decreased physical activity" is expected. Therefore, the composition of the present invention can prevent and / or improve frailty from physical and / or mental / psychological aspects, and as a result, can extend healthy life expectancy. It is presumed that such effects are obtained additively or synergistically by combining bacteria of the genus Bifidobacterium and bacteria of the genus Lacticaseibacillus.

[0032] Another aspect of the present invention is the use of Bifidobacterium and Lacticaseibacillus bacteria in the manufacture of a composition for extending healthy lifespan. Another aspect of the present invention is the use of Bifidobacterium and Lacticaseibacillus bacteria in extending healthy lifespan. Another aspect of the present invention is a Bifidobacterium or Lacticaseibacillus bacterium for use in extending healthy lifespan. Another aspect of the present invention is a method for extending healthy lifespan, comprising administering to a subject bacteria of the genus Bifidobacterium and bacteria of the genus Lacticaseibacillus.

[0033] The subject to which the composition of the present invention is administered (recipient) and the subject to which the composition is ingested (recipient) are not particularly limited as long as they are animals, but are usually humans. In addition, they may be adults, children, infants, newborns, etc., but are usually adults, and preferably elderly people (65 years or older). In addition, there is no particular limit to the gender.

[0034] In this specification, "administering Bifidobacterium bacteria and Lacticaseibacillus bacteria to an animal" may be synonymous with "allowing an animal to ingest Bifidobacterium bacteria and Lacticaseibacillus bacteria." Ingestion is usually voluntary (free intake), but may be forced (forced intake). That is, the administration step may specifically be, for example, a step of blending Bifidobacterium bacteria and Lacticaseibacillus bacteria into food, drink, or feed and supplying the mixture to a subject, thereby allowing the subject to ingest the mixture freely.

[0035] The timing of intake (administration) of the composition of the present invention is not particularly limited, and can be appropriately selected depending on the condition of the subject to be taken (administered).

[0036] The intake (administration) amount of the composition of the present invention is appropriately selected depending on the age, sex, condition, other conditions, etc. of the subject to be ingested (administered). The intake (administration) amount of the composition of the present invention is, for example, 1 × 10 for adults as the intake (administration) amount of the Bifidobacterium bacteria according to the present invention. 7 ~1×10 12 cfu / day range is preferred, with 1×10 8 ~1×10 11 A range of 1×10 cfu / day is more preferred. 9 ~1×10 11 cfu / day is more preferable. In addition, the intake (administration) amount of Lacticaceobacillus bacteria is, for example, 1×10 7 ~1×10 12 cfu / day The range of 1×10 is preferable. 8 ~1×10 11 A range of 1×10 cfu / day is more preferred. 9 ~1×1011 cfu / day is more preferred. Alternatively, the intake (administration) amount of the culture supernatant of Bifidobacterium genus bacteria is, for example, preferably in the range of 0.5 to 5 g / day for adults, more preferably in the range of 1 to 4 g / day, and even more preferably in the range of 2 to 3 g / day.The intake (administration) amount of the culture supernatant of Lacticaseibacillus genus bacteria is, for example, preferably in the range of 0.5 to 5 g / day for adults, more preferably in the range of 1 to 4 g / day, and even more preferably in the range of 2 to 3 g / day. Regardless of the amount or period of ingestion (administration), the composition of the present invention can be ingested (administered) once a day or in multiple divided doses.

[0037] The intake (administration) period of the composition of the present invention is not particularly limited. In addition, there is no particular upper limit to the intake (administration) period, and continuous, long-term intake (administration) is possible.

[0038] The composition of the present invention may be administered orally or parenterally, preferably orally. Examples of parenteral administration include transdermal, intravenous, rectal, and inhalation.

[0039] When the composition of the present invention is intended to be orally ingested (administered), it is preferably in the form of a food or drink.

[0040] There are no particular limitations on the form or properties of the food and beverage products as long as they do not impair the effects of the present invention and can be orally ingested (administered). Except for containing Bifidobacterium genus bacteria and Lacticaseibacillus genus bacteria, the food and beverage products can be produced by conventional methods using raw materials typically used for food and beverage products.

[0041] Food and drink products include, regardless of their form, liquid, paste, gel, solid, powder, etc., for example, nutritional supplements, tablet confectioneries; liquid foods (nutritional foods for tube feeding); wheat flour products such as bread, macaroni, spaghetti, noodles, cake mix, fried chicken powder, breadcrumbs, etc.; instant noodles, cup noodles, retort / prepared foods, pre-cooked canned foods, microwave foods, instant soup / stew, instant miso soup / cleansing liquid, canned soup, freeze-dried foods, other instant foods, etc.; Agricultural processed products such as canned agricultural products, canned fruit, jams and marmalades, pickles, boiled beans, dried agricultural goods, cereals (processed grain products), etc.; marine processed products such as canned seafood, fish ham and sausages, seafood paste products, seafood delicacies, tsukudani (fish stew), etc.; livestock processed products such as canned livestock pastes, livestock ham and sausages, etc.; dairy products such as processed milk, milk drinks, yogurt, lactic acid bacteria drinks, cheese, ice cream, modified milk powder, cream, other dairy products, etc.; butter, margarines, vegetable oils Fats and oils; basic seasonings such as soy sauce, miso, sauces, processed tomato seasonings, mirin, vinegars; complex seasonings and foods such as cooking mixes, curry bases, sauces, dressings, noodle soups, spices, and other complex seasonings; frozen foods such as raw frozen foods, semi-cooked frozen foods, and cooked frozen foods; caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese sweets, rice snacks, bean snacks, desserts These include sweets such as candy, jellies, and other snacks; beverages such as carbonated drinks, natural fruit juice, fruit juice drinks, soft drinks with fruit juice, fruit pulp drinks, fruit drinks with fruit particles, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks, sports drinks, nutritional drinks, alcoholic drinks, and other beverages, other commercially available foods such as baby food, furikake, and ochazuke nori; infant formula; enteral nutrition; functional foods (foods for specified health uses, foods with nutritional functions), etc.

[0042] In addition, one aspect of the food and drink may be feed, such as pet food, livestock feed, and fish feed. The form of the feed is not particularly limited, and may be Bifidobacterium genus and Lacticacea japonica. In addition to the Tillus bacteria, the food additive may contain, for example, grains such as corn, wheat, barley, rye, milo, etc.; vegetable oil cakes such as soybean oil cake, rapeseed oil cake, palm oil cake, linseed oil cake, etc.; bran such as wheat bran, wheat bran, rice bran, defatted rice bran, etc.; manufacturing residues such as corn gluten meal and corn jam meal; animal feeds such as fish meal, skim milk powder, casein, yellow grease, tallow, etc.; yeasts such as torula yeast and brewer's yeast; mineral feeds such as calcium phosphate, calcium carbonate, etc.; oils and fats; simple amino acids; sugars, etc.

[0043] When the composition of the present invention is in the form of a food or drink (including feed), it can be provided and sold as a food or drink labeled with an application for extending healthy lifespan.

[0044] Such "indication" acts include all acts for informing consumers of the above-mentioned uses, and any expression that can recall or infer the above-mentioned uses falls under the category of "indication" acts in this invention, regardless of the purpose of the indication, the content of the indication, the object or medium on which it is displayed, etc. Furthermore, it is preferable that the "labeling" be done in an expression that allows consumers to directly recognize the above-mentioned uses.Specific examples include the act of transferring, delivering, displaying for the purpose of transferring or delivering, or importing food and beverage products or product packaging on which the above-mentioned uses are written, displaying or distributing advertisements, price lists, or transaction documents related to the products and writing the above-mentioned uses in information containing the above-mentioned uses and providing them by electromagnetic means (such as the Internet), etc.

[0045] On the other hand, the content of the labeling is preferably a labeling approved by the government etc. (for example, a labeling approved based on various systems established by the government and made in a manner based on such approval, etc.) In addition, it is preferable that such a labeling content is affixed to the packaging, containers, catalogs, pamphlets, POP and other sales site promotional materials, other documents, etc.

[0046] In addition, "labeling" also includes labeling as health food, functional food, enteral nutrition food, special purpose food, health functional food, food for specified health uses, nutrient functional food, functional food, quasi-drug, etc. Among these, in particular, labeling approved by the Consumer Affairs Agency, for example, labeling approved under the system related to food for specified health uses, nutrient functional food, or functional food labeling, or a similar system, can be mentioned. Specifically, labeling as food for specified health uses, labeling as food for conditional specified health uses, labeling that affects the structure or function of the body, labeling for reducing disease risk, labeling of functionality based on scientific evidence, etc. can be mentioned. More specifically, labeling as food for specified health uses (especially labeling of health uses) and similar labeling as specified in the Cabinet Office Ordinance on the Permission of Labeling for Special Uses Prescribed in the Health Promotion Act (Cabinet Office Ordinance No. 57 of August 31, 2009) are typical examples.

[0047] Examples of such claims include "for those who wish to extend their healthy life expectancy," "for preventing and improving physical and mental aging," "measures against frailty," and "prevention of frailty." EXAMPLES

[0048] The present invention will be described in more detail below using examples, but the present invention is not limited to these examples.

[0049] [Test Example 1] Examination of the effect of extending healthy lifespan (1) Test method A test of administering the composition of the present invention to humans was carried out according to the following procedure. This test was carried out at Takara Clinic, Seishinkai Medical Corporation, with the approval of the clinic's ethics committee, in accordance with the spirit of the Declaration of Helsinki. The subjects were Japanese men and women aged 65 or older who lived at home and had bowel movements 2-5 times per week. The contents of the study were fully explained to participants, and informed consent was obtained. The following conditions were excluded from the study: (a) those currently undergoing treatment for or with a history of malignant tumors, (b) those currently undergoing treatment for or with a history of autoimmune diseases, and (c) those currently undergoing treatment for or with a history of inflammatory bowel disease. (d) people who are hospitalized, (e) people who regularly consume foods with specified health uses or functional claims, (f) people who regularly consume natto, yogurt, or foods / drinks containing lactic acid bacteria, (g) smokers, (h) people who regularly use anti-allergy medications, (i) people who regularly use laxatives, (j) people who regularly use foods with specified health uses or functional claims, (k) People who regularly use supplements that are thought to have functional properties other than those of foods with functional claims, (l) Those who are pregnant, breastfeeding, or pregnant during the study period. (m) Those who have participated in other clinical trials within the three months prior to the date of obtaining consent. (n) Anyone who the investigator judges to be inappropriate for this study. The intake group analyzed consisted of 28 people (10 men, 18 women, 71.0±4.5 years old).

[0050] The subjects were asked to take the test composition once a day after breakfast for four weeks. A non-taking group (29 subjects) was also included in parallel. The test composition is in powder form, and each dose (1.5 g) contains Bifidobacterium longum NI It contains 10 billion live cells of TE BP-02621, 10 billion killed cells of Lactobacillus paracasei NITE BP-01633, 300 mg of lactulose, and 0.15 g of dietary fiber. Before and four weeks after starting the intake, participants were asked to evaluate various subjective symptoms using a questionnaire (Likert scale method). The evaluation was done on a 6-point scale: 1: Not at all applicable, 2: Hardly applicable, 3: Not really applicable, 4: Applies a little, 5: Applies quite a bit, 6: Applies very much. In addition, before and 4 weeks after the start of intake, body measurements and physical examinations were performed. As one of the measurements, muscle mass was measured using ZEUS 9.9 (manufactured by Kobe Medicare Co., Ltd.).

[0051] (2) Results Significant improvements were observed after taking the test composition compared to before ingestion in the categories of "I'm worried about not being able to sleep," "I have no appetite," and "I still feel tired even after two days of rest" (Table 1). In addition, a significant improvement was observed in the category of "I still feel tired even after two days of rest" compared to the non-taken group (P<0.008). A significant increase in muscle mass was observed after taking the test composition compared to before (Table 2). A significant increase in muscle mass was also observed in comparison with the non-taking group (P<0.017).

[0052] [Table 1]

[0053] [Table 2]

Claims

1. A composition for preventing and / or improving frailty, comprising live Bifidobacterium longum NITE BP-02621 bacteria, killed Lactobacillus paracasei NITE BP-01633 bacteria, and prebiotics.

2. The composition of claim 1 , wherein the prebiotic is lactulose.

3. The composition according to claim 1 or 2, which is a food or drink.

Citation Information

Patent Citations

  • Composition for intestinal regulation

    JP2019116423A

  • Novel lactic acid bacterium, and pharmaceutical, food or drink, and feed, each containing novel lactic acid bacterium

    WO2012133827A1

  • Novel lactobacillus and novel lactobacillus-containing medicine, food, beverage and feed

    WO2015004949A1